Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABILIFY MYCITE KIT vs METHOHEXITAL SODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aripiprazole is a partial agonist at D2 and D3 dopamine receptors and 5-HT1A serotonin receptors, and an antagonist at 5-HT2A serotonin receptors. It also exhibits moderate affinity for histamine H1 receptors and alpha1-adrenergic receptors. The My Cite kit includes a sensor that detects tablet ingestion and transmits data to a wearable patch.
Methohexital sodium is a barbiturate that acts as a GABA-A receptor agonist, enhancing chloride conductance and causing neuronal hyperpolarization. It produces rapid sedation and anesthesia by depressing the central nervous system.
Schizophrenia,Acute manic/mixed episodes associated with bipolar I disorder,Maintenance treatment of bipolar I disorder,Major depressive disorder (adjunctive therapy),Irritability associated with autistic disorder,Tourette's disorder
Induction of anesthesia (FDA-approved),Maintenance of anesthesia (as an adjunct) (FDA-approved),Procedural sedation (off-label),Treatment of refractory status epilepticus (off-label)
Oral: 10-15 mg once daily; dose range 5-30 mg/day; titrate based on response and tolerability. The MYCITE sensor is applied to the tablet; the patch and app are for adherence monitoring only.
Induction of anesthesia: 1-1.5 mg/kg IV bolus over 15-30 seconds. Maintenance: intermittent IV boluses of 20-40 mg every 4-7 minutes as needed.
Aripiprazole: 75 hours (range 48–146 h). Dehydro-aripiprazole: 94 hours (range 48–206 h). Steady state reached in 14 days.
Terminal elimination half-life is 1.6–4.8 hours (mean ~3.9 hours) in adults. Context: Rapid redistribution shortens clinical duration; elimination half-life is longer in elderly and hepatic impairment.
Aripiprazole is metabolized primarily by CYP2D6 and CYP3A4. The major active metabolite is dehydro-aripiprazole (formed by CYP2D6). Phase I reactions include dehydrogenation and hydroxylation. Phase II glucuronidation of hydroxylated metabolites occurs.
Primarily hepatic metabolism via CYP2B6 and other microsomal enzymes; undergoes oxidation and glucuronidation. Active metabolites are minimally important.
Aripiprazole: ~25% renal, ~55% fecal; unchanged drug accounts for <1% renal. Dehydro-aripiprazole (active metabolite): excreted similarly.
Renal: <1% unchanged; hepatic metabolism followed by renal excretion of metabolites accounts for >95% of elimination. Fecal: negligible (<1%).
Aripiprazole: >99% bound to albumin and alpha-1-acid glycoprotein. Dehydro-aripiprazole: >99% bound.
85–90% bound to albumin.
Aripiprazole: 4.9 L/kg (IV). High Vd indicates extensive tissue distribution.
2.0–3.0 L/kg; context: High Vd due to extensive tissue distribution, especially to adipose tissue.
Oral: 87% (absolute). Tablet and orally disintegrating tablet are bioequivalent.
Intramuscular: ~90–100%; Rectal: ~70–80%; Oral: not available (inactive due to first-pass metabolism).
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥15 m L/min). Not recommended for severe renal impairment (Cr Cl <15 m L/min) due to lack of data.
No specific dose adjustment required for GFR 30-89 m L/min. For GFR <30 m L/min or dialysis: use with caution; consider reduced dose due to potential prolonged effect.
Child-Pugh Class A or B: No dose adjustment necessary. Child-Pugh Class C: Use with caution; maximum dose 10 mg/day due to increased exposure.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 25-50%. Child-Pugh Class C: use alternative agent or reduce dose by 50% with careful titration.
Not approved for patients <18 years; safety and effectiveness not established.
Induction: 1-2 mg/kg IV bolus. Maintenance: 0.5-1 mg/kg IV bolus as needed. Maximum single dose: 100 mg.
No specific dose adjustment; use lower starting doses (e.g., 5 mg/day) due to increased sensitivity and risk of adverse effects, especially orthostatic hypotension and tardive dyskinesia.
Reduce initial dose by 25-50% (0.5-1 mg/kg IV) and titrate slowly due to increased sensitivity and prolonged recovery.
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Aripiprazole is not approved for the treatment of patients with dementia-related psychosis.
Risk of respiratory depression and apnea; intravenous administration should be performed only by persons trained in the use of general anesthetics and able to maintain a patent airway and support ventilation. Continuous monitoring of respiratory function is required.
Neuroleptic malignant syndrome,Tardive dyskinesia,Metabolic changes including hyperglycemia/diabetes, dyslipidemia, weight gain,Orthostatic hypotension,Falls,Leukopenia/neutropenia/agranulocytosis,Seizures,Body temperature regulation impairment,Dysphagia,Suicidal thoughts/behaviors in adolescents/young adults with MDD
Respiratory depression and apnea,Hypotension and bradycardia,Injection site reactions (thrombophlebitis, necrosis, extravasation),Risk of emergence delirium and postoperative confusion,Laryngospasm and bronchospasm,Accumulation with repeated doses in patients with hepatic or renal impairment
Hypersensitivity to aripiprazole or any component of the formulation,Concurrent use with ziprasidone (QT prolongation risk)
Hypersensitivity to methohexital or other barbiturates,Acute intermittent porphyria or porphyria variegata,Uncontrolled severe hypotension or shock,Status asthmaticus,Severe respiratory insufficiency,Known or suspected massive drug overdose
No specific food interactions are reported for the sensor component. Aripiprazole can be taken with or without food. However, avoid excessive alcohol consumption as it may increase central nervous system depression or worsen side effects. Grapefruit and grapefruit juice do not significantly interact with aripiprazole metabolism (CYP3A4 minor pathway); no restriction needed.
No specific food interactions are documented for methohexital sodium. However, it is recommended to avoid heavy meals immediately before anesthesia to reduce risk of aspiration. Grapefruit juice may theoretically increase barbiturate levels by inhibiting CYP3A4, though clinical significance is unclear. Always follow pre-operative fasting instructions.
First trimester: Limited human data; animal studies show developmental toxicity (reduced fetal weight, delayed ossification) at doses similar to human exposure. Second/third trimester: Neonates exposed to antipsychotics (including aripiprazole) during late pregnancy may experience extrapyramidal symptoms and/or withdrawal symptoms (agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder).
Methohexital sodium is a barbiturate anesthetic. Use in the first trimester may be associated with a small increased risk of major malformations based on limited human data; animal studies show developmental toxicity at high doses. In the second and third trimesters, there is a risk of fetal depression and neonatal withdrawal if used chronically near term. Avoid in first trimester if possible; use only if clearly needed.
Aripiprazole is present in human breast milk; limited data suggest infant serum levels are low but can vary. M/P ratio not established. Caution advised; monitor infant for sedation, irritability, and feeding problems.
Methohexital enters breast milk in low amounts; the infant dose is estimated at <1% of maternal weight-adjusted dose. M/P ratio is approximately 0.5. Due to potential for neonatal sedation and the drug's short half-life, breastfeeding should be avoided for at least 4-6 hours after maternal administration.
No specific dose adjustment recommended; however, pregnancy may alter aripiprazole pharmacokinetics (decreased exposure due to increased volume of distribution and clearance). Monitor clinical response and consider dose adjustment if efficacy or tolerability changes. Use lowest effective dose.
Pregnancy may alter pharmacokinetics: increased volume of distribution and clearance may require slightly higher initial doses for induction, but no specific dose adjustment is recommended; titrate to effect. Use lowest effective dose due to potential for fetal depression.
Abilify My Cite is aripiprazole tablets embedded with an ingestible sensor (Ingestible Event Marker, IEM) that communicates with a wearable patch to record medication ingestion. It is used for schizophrenia, bipolar I disorder, and as adjunctive therapy for major depressive disorder. The sensor does not monitor drug levels or efficacy; it only confirms ingestion. Ensure the patient has a compatible smartphone and the My Cite app. The patch must be replaced weekly. Avoid MRI, CT, or diathermy near the patch; remove if undergoing these procedures. Monitor for aripiprazole side effects: akathisia, metabolic changes, tardive dyskinesia, and neuroleptic malignant syndrome. The ingestible sensor contains copper, magnesium, and silicon; allergy risk is low but possible.
METHOHEXITAL SODIUM is an ultra-short-acting barbiturate used for induction of general anesthesia. It has a rapid onset (less than 30 seconds) and short duration (5-10 minutes) due to redistribution. It is highly protein-bound and should be used with caution in patients with hypoalbuminemia. Contraindicated in porphyria. Avoid extravasation as it is a tissue irritant. May cause apnea, laryngospasm, and hypotension. Dose reduction needed in elderly or debilitated patients.
Take Abilify My Cite by mouth as directed. The sensor in the tablet activates upon contact with stomach fluid. Wear the My Cite patch on your left upper abdomen, replacing it weekly. Use the My Cite app to scan the tablet's QR code and confirm ingestion. Do not crush or chew the tablet. If a dose is missed, take it as soon as remembered unless it is close to the next dose. Do not double doses.,The patch is not MRI compatible; remove it before any MRI, CT scan, or diathermy procedure. Inform all healthcare providers that you use this system. The patch contains no latex. You may feel a mild sensation when the patch communicates with your phone. Keep your phone nearby (within Bluetooth range) for recording.,Common side effects of aripiprazole include nausea, vomiting, constipation, headache, dizziness, insomnia, restlessness, and weight gain. Seek medical attention for severe muscle stiffness, fever, confusion, irregular heartbeat, or suicidal thoughts. Avoid alcohol and activities requiring mental alertness until you know how this medication affects you.,The ingestible sensor is generally safe, but if you have a sensitivity to copper, magnesium, or silicon, discuss with your doctor. The patch may cause skin irritation; if it persists, stop use and contact your provider.,Do not rely solely on the app to confirm ingestion; it is not a substitute for clinical judgment. Store tablets at room temperature, away from moisture and heat. Keep out of reach of children.
This medication will cause you to lose consciousness quickly and is only given by a healthcare professional.,You will be closely monitored during and after administration.,You may experience drowsiness, dizziness, or confusion after waking up; do not drive or operate machinery for 24 hours.,Inform your doctor if you have any allergies, porphyria, or liver/kidney disease.,Avoid alcohol and other sedatives for at least 24 hours after receiving this medication.
No interactions on record
"The combination of methohexital, a barbiturate anesthetic, and mesoridazine, a phenothiazine antipsychotic, can lead to additive central nervous system (CNS) depression and respiratory depression due to synergistic pharmacodynamic effects on GABAergic and dopaminergic pathways. This interaction may result in enhanced sedation, hypotension, and increased risk of respiratory arrest, particularly during induction or maintenance of anesthesia. Patients with underlying respiratory or cardiovascular compromise are at heightened risk for severe adverse outcomes."
"Methohexital, a barbiturate anesthetic, induces cytochrome P450 (CYP) 3A4 enzyme activity, accelerating the hepatic metabolism of azelnidipine, a dihydropyridine calcium channel blocker. This results in reduced plasma concentrations and diminished antihypertensive efficacy of azelnidipine, potentially leading to inadequate blood pressure control during concurrent use."
"Concomitant use of Methohexital, a barbiturate anesthetic with central nervous system (CNS) depressant effects, and Guanfacine, an alpha-2 adrenergic agonist with sedative properties, can lead to additive CNS depression. This may result in enhanced sedation, respiratory depression, hypotension, and bradycardia. Patients may experience excessive drowsiness, impaired cognitive and motor function, and increased risk of falls or respiratory compromise, particularly during anesthesia induction or recovery."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABILIFY MYCITE KIT vs METHOHEXITAL SODIUM, answered by our medical review team.
ABILIFY MYCITE KIT is a Atypical antipsychotic that works by Aripiprazole is a partial agonist at D2 and D3 dopamine receptors and 5-HT1A serotonin receptors, and an antagonist at 5-HT2A serotonin receptors. It also exhibits moderate affinity for histamine H1 receptors and alpha1-adrenergic receptors. The My Cite kit includes a sensor that detects tablet ingestion and transmits data to a wearable patch.. METHOHEXITAL SODIUM is a Barbiturate Anesthetic that works by Methohexital sodium is a barbiturate that acts as a GABA-A receptor agonist, enhancing chloride conductance and causing neuronal hyperpolarization. It produces rapid sedation and anesthesia by depressing the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABILIFY MYCITE KIT and METHOHEXITAL SODIUM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABILIFY MYCITE KIT is: Oral: 10-15 mg once daily; dose range 5-30 mg/day; titrate based on response and tolerability. The MYCITE sensor is applied to the tablet; the patch and app are for adherence monitoring only.. The standard adult dose of METHOHEXITAL SODIUM is: Induction of anesthesia: 1-1.5 mg/kg IV bolus over 15-30 seconds. Maintenance: intermittent IV boluses of 20-40 mg every 4-7 minutes as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABILIFY MYCITE KIT and METHOHEXITAL SODIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABILIFY MYCITE KIT is classified as Category C. First trimester: Limited human data; animal studies show developmental toxicity (reduced fetal weight, delayed ossification) at doses similar to human exposure. Second/third trimes. METHOHEXITAL SODIUM is classified as Category C. Methohexital sodium is a barbiturate anesthetic. Use in the first trimester may be associated with a small increased risk of major malformations based on limited human data; animal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.